Actionable news
All posts from Actionable news
Actionable news in PFE: PFIZER Inc,

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

Before the bell rings Tuesday morning pharmacy giant Pfizer Inc. (PFE) is expected to have released their second-quarter earnings, where a lot of eyeballs will be delving into the company's pipeline.

Analysts speculate that earnings may climb by a cent or two and that the company could report $13.02 billion in revenue, and earnings per share of about 65 cents, according to analysts polled by FactSet Research. Shares of Pfizer currently trade at $33.28 apiece. The company is up 0.84% year-to-date, though the stock is down 10.8% year-over-year.

Credit Suisse analysts noted that there is "limited near-term upside potential" and that they were weary of the company given looming patent expirations of Viagra (sildenafil citrate), used for erectile dysfunction, and Lyrica (pregabalin), used for neuropathic pain/fibromyalgia, are swooping in December 2017 and December 2018, respectively -- which could stunt growth if not addressed by the company.

To be sure, the Viagra patent is not up until 2020 though Teva Pharmaceutical Industries Ltd. (TEVA) will have the opportunity to manufacture a generic version starting in December 2017.

Credit Suisse switched their rating from "Outperform" to "Neutral," on Thursday, July 27. The analysts...